Develops drugs for neurological and rare diseases.
Jun 2026Revenue $1.14B/yrExpenses $1.05B/yr
Reached break-even Apr 2024
Figures by year
When did Acadia Pharmaceuticals become profitable?
Its revenue passed its expenses in Apr 2024. In the 12 months to Jun 2026, revenue was $1.14B and expenses $1.05B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $1.07B | $967M | $105M |
| Dec 2024 | $958M | $727M | $231M |
| Dec 2023 | $726M | $800M | −$73.4M |
| Dec 2022 | $517M | $741M | −$224M |
| Dec 2021 | $484M | $655M | −$170M |
| Dec 2020 | $442M | $728M | −$287M |
| Dec 2019 | $339M | $586M | −$247M |
| Dec 2018 | $224M | $471M | −$247M |
| Dec 2017 | $125M | $417M | −$292M |
| Dec 2016 | $17.3M | $290M | −$273M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.